Survival and prognostic factors in adult patients with recurrent or refractory ewing sarcoma family tumours: a 13-years retrospective study in Turkey
The aim of the present study was to evaluate the results of treatment and prognostic factors in adult patients with recurrent or refractory Ewing's sarcoma family tumors (ESFT). We retrospectively evaluated treatment outcomes of 54 consecutive patients with ESFT (aged 15 years or more) with com...
Gespeichert in:
| Veröffentlicht in: | In vivo (Athens) 2014-05, Vol.28 (3), p.403-409 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 409 |
|---|---|
| container_issue | 3 |
| container_start_page | 403 |
| container_title | In vivo (Athens) |
| container_volume | 28 |
| creator | Yildiz, Ibrahim Sen, Fatma Ekenel, Meltem Darendeliler, Emin Bavbek, Sevil Agaoglu, Fulya Ozger, Harzem Eralp, Levent Bilgic, Bilge Basaran, Mert |
| description | The aim of the present study was to evaluate the results of treatment and prognostic factors in adult patients with recurrent or refractory Ewing's sarcoma family tumors (ESFT).
We retrospectively evaluated treatment outcomes of 54 consecutive patients with ESFT (aged 15 years or more) with complete medical records, who were treated with multimodal therapies after recurrence at the Istanbul University, Institute of Oncology.
The commonly used chemotherapy regimens at relapse were ifosfamide and etoposide (IE), ifosfamide and etoposide plus carboplatin (ICE), and oral etoposide. The median progression-free survival and overall survival for the entire group were 6.3 (95% confidence interval, 3.08-9.60) and 8.6 (95% confidence interval CI, 4.7-12.4) months, respectively. Multivariate analysis using a Cox proportional hazards model showed that non-IE/ICE chemotherapy regimens (p=0.003, hazard ratio=2.38) and the presence extrapulmonary metastases (p=0.045, hazard ratio=2.15) were associated with worse overall survival.
In primary refractory or relapsed ESFT, the presence of extrapulmonary metastases and treatment with salvage regimens other than ifosfamide and etoposide and/or carboplatin correlate with a poor prognosis. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1524159409</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1524159409</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-452f1dae853274363e04dc61327ff58b398f5dd9c55cf24691272b3c3a877d723</originalsourceid><addsrcrecordid>eNo1kMtKxDAUQIsgzjj6C5Klm0Lzalp3MviCAReO65LJY4y2Tb1JOvRD_F-rjqvLgcO53HuSLbGocS44qxfZeQjvRVGKoiBn2YKwCvOK8WX29ZJgdKNskew1GsDvex-iU8hKFT0E5HokdWojGmR0po8BHVx8Q2BUApgZeZjBwq8-IXNw_R4FCcp3co50rp1QTJ1PEG6QRJjmk5FzF0wEHwajohsNCjHp6WfXNsGHmS6yUyvbYC6Pc5W93t9t14_55vnhaX27yQeCccwZJxZraSpOiWC0pKZgWpV4Jmt5taN1ZbnWteJcWcLKGhNBdlRRWQmhBaGr7PqvOx_-mUyITeeCMm0re-NTaDAnDPOaFfWsXh3VtOuMbgZwnYSp-X8l_Qblv3H_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1524159409</pqid></control><display><type>article</type><title>Survival and prognostic factors in adult patients with recurrent or refractory ewing sarcoma family tumours: a 13-years retrospective study in Turkey</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Yildiz, Ibrahim ; Sen, Fatma ; Ekenel, Meltem ; Darendeliler, Emin ; Bavbek, Sevil ; Agaoglu, Fulya ; Ozger, Harzem ; Eralp, Levent ; Bilgic, Bilge ; Basaran, Mert</creator><creatorcontrib>Yildiz, Ibrahim ; Sen, Fatma ; Ekenel, Meltem ; Darendeliler, Emin ; Bavbek, Sevil ; Agaoglu, Fulya ; Ozger, Harzem ; Eralp, Levent ; Bilgic, Bilge ; Basaran, Mert</creatorcontrib><description>The aim of the present study was to evaluate the results of treatment and prognostic factors in adult patients with recurrent or refractory Ewing's sarcoma family tumors (ESFT).
We retrospectively evaluated treatment outcomes of 54 consecutive patients with ESFT (aged 15 years or more) with complete medical records, who were treated with multimodal therapies after recurrence at the Istanbul University, Institute of Oncology.
The commonly used chemotherapy regimens at relapse were ifosfamide and etoposide (IE), ifosfamide and etoposide plus carboplatin (ICE), and oral etoposide. The median progression-free survival and overall survival for the entire group were 6.3 (95% confidence interval, 3.08-9.60) and 8.6 (95% confidence interval CI, 4.7-12.4) months, respectively. Multivariate analysis using a Cox proportional hazards model showed that non-IE/ICE chemotherapy regimens (p=0.003, hazard ratio=2.38) and the presence extrapulmonary metastases (p=0.045, hazard ratio=2.15) were associated with worse overall survival.
In primary refractory or relapsed ESFT, the presence of extrapulmonary metastases and treatment with salvage regimens other than ifosfamide and etoposide and/or carboplatin correlate with a poor prognosis.</description><identifier>EISSN: 1791-7549</identifier><identifier>PMID: 24815845</identifier><language>eng</language><publisher>Greece</publisher><subject>Adolescent ; Adult ; Bone Neoplasms - mortality ; Bone Neoplasms - pathology ; Bone Neoplasms - therapy ; Combined Modality Therapy ; Family ; Female ; Humans ; Male ; Neoplasm Staging ; Prognosis ; Recurrence ; Retrospective Studies ; Sarcoma, Ewing - mortality ; Sarcoma, Ewing - pathology ; Sarcoma, Ewing - therapy ; Time Factors ; Treatment Outcome ; Tumor Burden ; Turkey ; Young Adult</subject><ispartof>In vivo (Athens), 2014-05, Vol.28 (3), p.403-409</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24815845$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yildiz, Ibrahim</creatorcontrib><creatorcontrib>Sen, Fatma</creatorcontrib><creatorcontrib>Ekenel, Meltem</creatorcontrib><creatorcontrib>Darendeliler, Emin</creatorcontrib><creatorcontrib>Bavbek, Sevil</creatorcontrib><creatorcontrib>Agaoglu, Fulya</creatorcontrib><creatorcontrib>Ozger, Harzem</creatorcontrib><creatorcontrib>Eralp, Levent</creatorcontrib><creatorcontrib>Bilgic, Bilge</creatorcontrib><creatorcontrib>Basaran, Mert</creatorcontrib><title>Survival and prognostic factors in adult patients with recurrent or refractory ewing sarcoma family tumours: a 13-years retrospective study in Turkey</title><title>In vivo (Athens)</title><addtitle>In Vivo</addtitle><description>The aim of the present study was to evaluate the results of treatment and prognostic factors in adult patients with recurrent or refractory Ewing's sarcoma family tumors (ESFT).
We retrospectively evaluated treatment outcomes of 54 consecutive patients with ESFT (aged 15 years or more) with complete medical records, who were treated with multimodal therapies after recurrence at the Istanbul University, Institute of Oncology.
The commonly used chemotherapy regimens at relapse were ifosfamide and etoposide (IE), ifosfamide and etoposide plus carboplatin (ICE), and oral etoposide. The median progression-free survival and overall survival for the entire group were 6.3 (95% confidence interval, 3.08-9.60) and 8.6 (95% confidence interval CI, 4.7-12.4) months, respectively. Multivariate analysis using a Cox proportional hazards model showed that non-IE/ICE chemotherapy regimens (p=0.003, hazard ratio=2.38) and the presence extrapulmonary metastases (p=0.045, hazard ratio=2.15) were associated with worse overall survival.
In primary refractory or relapsed ESFT, the presence of extrapulmonary metastases and treatment with salvage regimens other than ifosfamide and etoposide and/or carboplatin correlate with a poor prognosis.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Bone Neoplasms - mortality</subject><subject>Bone Neoplasms - pathology</subject><subject>Bone Neoplasms - therapy</subject><subject>Combined Modality Therapy</subject><subject>Family</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Recurrence</subject><subject>Retrospective Studies</subject><subject>Sarcoma, Ewing - mortality</subject><subject>Sarcoma, Ewing - pathology</subject><subject>Sarcoma, Ewing - therapy</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Tumor Burden</subject><subject>Turkey</subject><subject>Young Adult</subject><issn>1791-7549</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMtKxDAUQIsgzjj6C5Klm0Lzalp3MviCAReO65LJY4y2Tb1JOvRD_F-rjqvLgcO53HuSLbGocS44qxfZeQjvRVGKoiBn2YKwCvOK8WX29ZJgdKNskew1GsDvex-iU8hKFT0E5HokdWojGmR0po8BHVx8Q2BUApgZeZjBwq8-IXNw_R4FCcp3co50rp1QTJ1PEG6QRJjmk5FzF0wEHwajohsNCjHp6WfXNsGHmS6yUyvbYC6Pc5W93t9t14_55vnhaX27yQeCccwZJxZraSpOiWC0pKZgWpV4Jmt5taN1ZbnWteJcWcLKGhNBdlRRWQmhBaGr7PqvOx_-mUyITeeCMm0re-NTaDAnDPOaFfWsXh3VtOuMbgZwnYSp-X8l_Qblv3H_</recordid><startdate>20140501</startdate><enddate>20140501</enddate><creator>Yildiz, Ibrahim</creator><creator>Sen, Fatma</creator><creator>Ekenel, Meltem</creator><creator>Darendeliler, Emin</creator><creator>Bavbek, Sevil</creator><creator>Agaoglu, Fulya</creator><creator>Ozger, Harzem</creator><creator>Eralp, Levent</creator><creator>Bilgic, Bilge</creator><creator>Basaran, Mert</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20140501</creationdate><title>Survival and prognostic factors in adult patients with recurrent or refractory ewing sarcoma family tumours: a 13-years retrospective study in Turkey</title><author>Yildiz, Ibrahim ; Sen, Fatma ; Ekenel, Meltem ; Darendeliler, Emin ; Bavbek, Sevil ; Agaoglu, Fulya ; Ozger, Harzem ; Eralp, Levent ; Bilgic, Bilge ; Basaran, Mert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-452f1dae853274363e04dc61327ff58b398f5dd9c55cf24691272b3c3a877d723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Bone Neoplasms - mortality</topic><topic>Bone Neoplasms - pathology</topic><topic>Bone Neoplasms - therapy</topic><topic>Combined Modality Therapy</topic><topic>Family</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Recurrence</topic><topic>Retrospective Studies</topic><topic>Sarcoma, Ewing - mortality</topic><topic>Sarcoma, Ewing - pathology</topic><topic>Sarcoma, Ewing - therapy</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Tumor Burden</topic><topic>Turkey</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yildiz, Ibrahim</creatorcontrib><creatorcontrib>Sen, Fatma</creatorcontrib><creatorcontrib>Ekenel, Meltem</creatorcontrib><creatorcontrib>Darendeliler, Emin</creatorcontrib><creatorcontrib>Bavbek, Sevil</creatorcontrib><creatorcontrib>Agaoglu, Fulya</creatorcontrib><creatorcontrib>Ozger, Harzem</creatorcontrib><creatorcontrib>Eralp, Levent</creatorcontrib><creatorcontrib>Bilgic, Bilge</creatorcontrib><creatorcontrib>Basaran, Mert</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>In vivo (Athens)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yildiz, Ibrahim</au><au>Sen, Fatma</au><au>Ekenel, Meltem</au><au>Darendeliler, Emin</au><au>Bavbek, Sevil</au><au>Agaoglu, Fulya</au><au>Ozger, Harzem</au><au>Eralp, Levent</au><au>Bilgic, Bilge</au><au>Basaran, Mert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival and prognostic factors in adult patients with recurrent or refractory ewing sarcoma family tumours: a 13-years retrospective study in Turkey</atitle><jtitle>In vivo (Athens)</jtitle><addtitle>In Vivo</addtitle><date>2014-05-01</date><risdate>2014</risdate><volume>28</volume><issue>3</issue><spage>403</spage><epage>409</epage><pages>403-409</pages><eissn>1791-7549</eissn><abstract>The aim of the present study was to evaluate the results of treatment and prognostic factors in adult patients with recurrent or refractory Ewing's sarcoma family tumors (ESFT).
We retrospectively evaluated treatment outcomes of 54 consecutive patients with ESFT (aged 15 years or more) with complete medical records, who were treated with multimodal therapies after recurrence at the Istanbul University, Institute of Oncology.
The commonly used chemotherapy regimens at relapse were ifosfamide and etoposide (IE), ifosfamide and etoposide plus carboplatin (ICE), and oral etoposide. The median progression-free survival and overall survival for the entire group were 6.3 (95% confidence interval, 3.08-9.60) and 8.6 (95% confidence interval CI, 4.7-12.4) months, respectively. Multivariate analysis using a Cox proportional hazards model showed that non-IE/ICE chemotherapy regimens (p=0.003, hazard ratio=2.38) and the presence extrapulmonary metastases (p=0.045, hazard ratio=2.15) were associated with worse overall survival.
In primary refractory or relapsed ESFT, the presence of extrapulmonary metastases and treatment with salvage regimens other than ifosfamide and etoposide and/or carboplatin correlate with a poor prognosis.</abstract><cop>Greece</cop><pmid>24815845</pmid><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1791-7549 |
| ispartof | In vivo (Athens), 2014-05, Vol.28 (3), p.403-409 |
| issn | 1791-7549 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1524159409 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adolescent Adult Bone Neoplasms - mortality Bone Neoplasms - pathology Bone Neoplasms - therapy Combined Modality Therapy Family Female Humans Male Neoplasm Staging Prognosis Recurrence Retrospective Studies Sarcoma, Ewing - mortality Sarcoma, Ewing - pathology Sarcoma, Ewing - therapy Time Factors Treatment Outcome Tumor Burden Turkey Young Adult |
| title | Survival and prognostic factors in adult patients with recurrent or refractory ewing sarcoma family tumours: a 13-years retrospective study in Turkey |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T18%3A30%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20and%20prognostic%20factors%20in%20adult%20patients%20with%20recurrent%20or%20refractory%20ewing%20sarcoma%20family%20tumours:%20a%2013-years%20retrospective%20study%20in%20Turkey&rft.jtitle=In%20vivo%20(Athens)&rft.au=Yildiz,%20Ibrahim&rft.date=2014-05-01&rft.volume=28&rft.issue=3&rft.spage=403&rft.epage=409&rft.pages=403-409&rft.eissn=1791-7549&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1524159409%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1524159409&rft_id=info:pmid/24815845&rfr_iscdi=true |